Home > Maligne hematologie > Myeloïde ziekten > Acute myeloïde leukemie > AML (incl. APL) > Hovon 150 (IDH2 cohort gesloten)

Hovon 150 (IDH2 cohort gesloten)

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

Deze print is 24 uur geldig na het aanmaken. Aangemaakt op: 14-6-2024, 23:57